

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Withdrawn) The use of a C-Raf inhibitor, or a pharmaceutically acceptable salt, complex or prodrug thereof, for the manufacture of a composition for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal cord injury.
2. (Withdrawn) The use of a C-Raf inhibitor, or a pharmaceutically acceptable salt, complex or prodrug thereof, for the manufacture of a composition for the repair or regeneration of neuronal cells in a mammal.
3. (Withdrawn) The use of a C-Raf inhibitor, or a pharmaceutically acceptable salt, complex or prodrug thereof, for the manufacture of a composition for the prevention or inhibition of apoptotic neuronal cell death.
4. (Withdrawn) The use of a C-Raf inhibitor, or a pharmaceutically acceptable salt, complex or prodrug thereof, for the manufacture of a composition for the prevention or inhibition of neuronal cell death potentiated by inhibition or suppression of B-Raf.
5. (Withdrawn) The use of a C-Raf inhibitor, or a pharmaceutically acceptable salt, complex or prodrug thereof, for the manufacture of a composition for preventing or inhibiting neuronal cell death by stimulating or activating B-Raf.
6. (Withdrawn) The use of a C-Raf inhibitor as claimed in claim 3 wherein the composition is for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy- associated neuronal loss, paralysis or spinal cord injury.
7. (Withdrawn) The use of a C-Raf inhibitor as claimed in claim 4 wherein the composition is for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury,

epilepsy- associated neuronal loss, paralysis or spinal cord injury.

8. (Withdrawn) The use of a C-Raf inhibitor as claimed in claim 5 wherein the composition is for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy- associated neuronal loss, paralysis or spinal cord injury.

9. (Withdrawn) The use as claimed in any one of claims 1 to 5, wherein the C-Raf inhibitor comprises an oxindole derivative, or a pharmaceutically acceptable salt, complex or prodrug thereof.

10. (Withdrawn) The use of claim 9, wherein said oxindole derivative further comprises {5-iodo-3- [(3, 5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}.

11. (Withdrawn) The use of claim 1, wherein said C-Raf inhibitor further comprises N-[5-(3-Dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide.

12. (Currently amended) A method of ~~at least partially inhibiting reducing~~ neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, ~~epilepsy associated neuronal loss~~, paralysis, or spinal cord injury, comprising administering to the mammal an effective amount of a 3-substituted indolones that is a C-Raf inhibitor or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof sufficient to reduce neuronal cell death.

13. (Withdrawn) A method of repairing or regenerating neuronal cells in a mammal in need thereof, comprising administering to the mammal an effective amount of a C-Raf inhibitor or a pharmaceutically acceptable salt, complex or prodrug thereof.

14. (Currently Amended) A method of ~~at least partially inhibiting reducing~~ apoptotic neuronal cell death in a mammal, comprising administering to the mammal an effective amount of a C-Raf inhibitor, or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

15. (Previously Presented) The method of claim 1714, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}.

16. (Withdrawn) A method of treating neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal cord injury,

comprising administering to the mammal an effective amount of a B-Raf activator or a pharmaceutically acceptable salt, complex or prodrug thereof.

17. (Currently Amended) The method of Claims 12 or 14 wherein said C-Raf inhibitor, or a pharmaceutically acceptable salt, complex or prodrug thereof, comprises an oxindole derivative, or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

18. (Currently Amended) The method of Claims 12 or 14 wherein said C-Raf inhibitor, or a pharmaceutically acceptable salt, complex or prodrug thereof, comprises a benzamide derivative, or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

19. (Previously Presented) The method of Claim 18 wherein said C-Raf inhibitor comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide.

20. (Currently amended) The method of Claims 12 or 14 wherein said C-Raf inhibitor or a pharmaceutically acceptable salt, complex or prodrug thereof, ~~prevents or inhibits reduces~~ neuronal cell death via B-Raf regulation.

21. (Currently Amended) The method of Claim 20, wherein said C-Raf inhibitor or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof ~~prevents or inhibits reduces~~ neuronal cell death by activating B-Raf.

22. (Currently Amended) The method of Claim 21, wherein said C-Raf inhibitor or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof comprises an oxindole derivative.

23. (Currently Amended) The method of Claim 22, wherein said C-Raf inhibitor comprises {5- iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone} or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

24. (Currently Amended) The method of Claim 20, wherein said C-Raf inhibitor or a pharmaceutically acceptable salt, complex or prodrug thereof, comprises a benzamide derivative, or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

25. (Currently Amended) The method of Claim 24, wherein said benzamide derivative comprises N-[5-(3- dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

26. (Currently Amended) The method of Claim 21, wherein said C-Raf inhibitor or a

pharmaceutically acceptable salt, complex or prodrug thereof, comprises a benzamide derivative, or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

27. (Currently Amended) The method of Claim 26, wherein said benzamide derivative comprises N-[5-(3-dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

28. (Currently Amended) A method of reducing neuronal cell death in a mammal, comprising administering an effective amount of a C-Raf inhibitor or a pharmaceutically acceptable salt, ~~complex or prodrug~~ thereof.

29. (Previously Presented) The method of Claim 28, wherein said C-Raf inhibitor comprises an oxindole derivative.

30. (Previously Presented) The method of Claim 28, wherein said C-Raf inhibitor comprises a benzamide derivative.

31. (Previously Presented) The method of Claims 28, wherein said C-Raf inhibitor reduces neuronal cell death via B-Raf regulation.

32. (Previously Presented) The method of Claim 31, wherein said C-Raf inhibitor reduces neuronal cell death by B-Raf activation.

33. (Previously Presented) The method of Claims 29 or 31 or 32, wherein said C-Raf inhibitor comprises {5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indolinone}.

34. (Previously Presented) The method of Claims 29 or 31 or 32, wherein said C-Raf inhibitor comprises N-[5-(3-dimethylaminobenzamide)-2-methylphenyl]-4-hydroxybenzamide.